# Oncology-based in vivo CRO Market

> Oncology-based in vivo CRO Market Research Report: Size, Share, Trend Analysis By Indication (Blood Cancer, Solid Tumors, and Others), By Model (Syngeneic Model, and Xenograft) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.3%
- **2024:** $ 1.4 Billion
- **2025:** $ 1.51 Billion
- **2035:** $ 3.36 Billion
- **Key Players:** Charles River Laboratories (US), Covance (US), PRA Health Sciences (US), Medpace (US), Eurofins Scientific (LU), Syneos Health (US), Wuxi AppTec (CN), OncoOne (CH), Kymab (GB)

**Report ID:** MRFR/HCIT/20123-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/oncology-based-in-vivo-cro-market-21721

---

## Market Summary

## **Oncology-based in vivo CRO Market Overview**

As per MRFR analysis, the Oncology-based in vivo CRO Market Size was estimated at 1.40 (USD Billion) in 2024. The Oncology-based in vivo CRO Market Industry is expected to grow from 1.51 (USD Billion) in 2025 to 3.10 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.30% during the forecast period (2025 - 2034). Advancement in clinical procedures, growing discovery of medications and novel therapy techniques are the key market drivers accelerating market expansion.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Oncology-based in vivo CRO Market Trends**

### **Increasing cancer incidences are driving the market growth**

Market CAGR for oncology-based in vivo CRO is being driven by the increase in the incidence of cancer. The study of cancer diagnosis, prevention, and therapy is known as oncology. In-vivo refers to within a living organism, and CRO stands for contract research organization. The management of cancer with the aid of contract research organization services is known as oncology-based in-vivo CRO.

Additionally, one of the key factors anticipated accelerating the growth and demand of the oncology-based in-vivo contract research organization (CRO) market is the increase in the prevalence of cancer around the world, a disease for which electrosurgical methods are appropriate. Additionally predicted during the forecast period of 2021 to 2028 is the straightforward availability of government funding for research and the rise in CROs' competence in treating cancer would both contribute to the expansion of the market. Additionally, a boost in the focus on oncogene research and an increase in genetic engineering discoveries are both anticipated to support market expansion.

In-vivo contract research organizations (CRO) based on oncology are expected to see significant growth opportunities within the anticipated window due to the rise in specific cancer treatments, the ease of access to a large percentage of medicines, and the rise in the use of these organizations for developing new cancer diagnoses and treatments. On the other hand, the high cost of clinical trials and strict regulatory approvals can impede the growth of the oncology-based in-vivo contract study organization (CRO) market.

Additionally, the high cost of cancer drugs and their negative side effects are anticipated to restrain the development of the oncology-based in-vivo contract research organization (CRO) market.

As an illustration, the World Health Organization projects that there will be 19.3 million additional instances of cancer worldwide in 2020, contributing to an estimated 10 million deaths. Due to this, businesses are outsourcing basic research tasks in order to boost efficiency and concentrate on important development areas. Thus, result in driving the oncology-based in vivo CRO market revenue.

## **Oncology-based in vivo CRO Market Segment Insights**

### **Oncology-based in vivo CRO Indication Insights**

The oncology-based in vivo [CRO market](../../../articles/cro-market-outlook) segmentation, based on Indication includes Blood cancer, Solid tumors, and Others. The solid tumors segment dominated the market. The motivation behind more research in the field of solid tumors is the existence of over 800 new drugs in the research pipeline being conducted by major pharmaceutical companies. Additionally, grants from organizations like the NIH and NCI are accessible, and the treatment gap for solid cancer continues to be one of the industry's most promising development drivers.

### **Oncology-based in vivo CRO Model Insights                             **

The oncology-based in vivo CRO market segmentation, based on Model, includes Syngeneic model and Xenograft. The syngeneic model category generated the most income. Tumors created by murine cancer cells grafted onto genetically similar mouse strains are known as syngeneic mouse models. They are frequently employed as instruments for researching [immunotherapy](../../../reports/cancer-immunotherapy-market-592) response and tumor immunity in the context of a fully developed murine immune system.

**Figure 1:  Oncology-based in vivo CRO Market, by Model, 2022 & 2032 (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Oncology-based in vivo CRO Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American oncology-based in vivo CRO market area will dominate this market. This can be ascribed to the high level of technological development among the CROs in this area. A federal organization called the National Institutes of Health (NIH) provides funding and grants to assist research initiatives. The highest per-capita healthcare spending is in the United States.

Further, the major countries studied in the market report are the US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

**Figure 2:  ONCOLOGY-BASED IN VIVO CRO MARKET SHARE BY REGION 2022 (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

Europe oncology-based in vivo CRO market takes second place in terms of market share due to the rise in R&D efforts and the requirement to cut back on overall trial expenses. Further, the German oncology-based in vivo CRO market held a dominant market share, and the UK oncology-based in vivo CRO market was the European region's fastest-growing market.

The Asia-Pacific Oncology-based in vivo CRO Market is anticipated to see the fastest CAGR between 2025 and 2034. This is due to untapped potential, a large patient base, economic growth, and a healthcare system that is constantly improving. Moreover, China’s oncology-based in vivo CRO market held a dominant market share, and the Indian oncology-based in vivo CRO market was the Asia-Pacific region's fastest-growing market.

## **Oncology-based in vivo CRO Key Market Players & Competitive Insights**

Leading market players are putting a lot of money on R&D to increase the number of products they offer, which will fuel the growth of the oncology-based in vivo CRO industry. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other businesses. To grow and endure in an increasingly competitive and challenging market environment, oncology-based in vivo CRO industry must provide reasonably priced goods.

One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the oncology-based in vivo CRO industry to develop market sector and provide benefits to customers. In recent years, the oncology-based in vivo CRO industry has provided some of the most important benefits for medicine. Major players in the oncology-based in vivo CRO market, including Biosciences, Charles River Laboratory (CRL), Covance, Crown Bioscience, Eurofins Scientific, ICON Plc, Taconic, and others, invest in operations for research and development in an effort to improve market demand.

Charles River Laboratories International, Inc. is a pharmaceutical firm based in the United States that offers a range of clinical and preclinical laboratory, gene therapy, and cell therapy services to the pharmaceutical, medical device, and biotechnology sectors. Additionally, it provides assistance with basic research, drug discovery, safety and efficacy, clinical support, production, and a range of biomedical products, outsourcing services, and animal research and development (for example, contract research organization services). Approximately 85% of unique FDA-approved medications in 2021, according to the business, were developed with support from them.

In 2019, The company announced that it would pay EUR 448 million (USD 500 million) in cash to acquire Citoxlab, together with the previous purchases of the French firm AccelLAB, Atlanbio, and Solvo Biotechnology.

Labcorp Drug Development is an agreement-based research organization (CRO) that offers nonclinical, preclinical, clinical, and commercialization services to the pharmaceutical and biotechnology sectors. The organization was once known as Covance and is a part of Labcorp, which has over 70,000 employees ly. The world's largest central laboratory network, according to Labcorp Drug Development, is available. Animal rights activists, such as Jane Goodall, have fought Labcorp Drug Development vehemently over their use of animals in testing. In 2019, Covance and Envigo came to an agreement for Covance to purchase the nonclinical research services division of Envigo.

Envigo acquired the research products division of Covance.

### **Key companies in the oncology-based in vivo CRO market include**

- Biosciences
- [Charles River Laboratory](https://www.criver.com/therapeutic-area/oncology) (CRL)
- Covance
- Crown Bioscience
- Eurofins Scientific
- ICON Plc
- Taconic
- The Jackson Laboratory
- Toxikon Inc.
- WuXi AppTec

## **Oncology-based In Vivo Cro Market Industry Developments**

- **Q2 2024: Charles River Laboratories Announces Opening of New Oncology Center of Excellence in Cambridge** Charles River Laboratories opened a new Oncology Center of Excellence in Cambridge, Massachusetts, aimed at expanding its in vivo oncology CRO capabilities and supporting preclinical cancer drug development.
- **Q2 2024: Crown Bioscience Expands In Vivo Oncology Services with New Facility in San Diego** Crown Bioscience announced the opening of a new facility in San Diego dedicated to in vivo oncology research, enhancing its capacity for preclinical CRO services in cancer drug discovery.
- **Q3 2024: WuXi AppTec Launches Advanced In Vivo Oncology Platform to Accelerate Immuno-Oncology Drug Development** WuXi AppTec launched a new in vivo oncology platform designed to support immuno-oncology drug development, offering expanded preclinical CRO services for pharmaceutical and biotech clients.
- **Q3 2024: Labcorp Acquires Preclinical Oncology CRO, Expands In Vivo Cancer Research Services** Labcorp completed the acquisition of a specialized preclinical oncology CRO, strengthening its in vivo cancer research service offerings for global biopharma clients.
- **Q4 2024: Evotec and Bristol Myers Squibb Announce Strategic Partnership for In Vivo Oncology Drug Discovery** Evotec entered a strategic partnership with Bristol Myers Squibb to collaborate on in vivo oncology drug discovery, leveraging Evotec’s CRO expertise to accelerate cancer therapy development.
- **Q4 2024: Syngene International Opens New Preclinical Oncology Research Facility in Bangalore** Syngene International inaugurated a new preclinical oncology research facility in Bangalore, expanding its in vivo CRO capabilities for global pharmaceutical clients.
- **Q1 2025: Eurofins Scientific Acquires Oncology-Focused CRO to Bolster In Vivo Cancer Research Portfolio** Eurofins Scientific acquired a US-based oncology-focused CRO, enhancing its in vivo cancer research services and expanding its global preclinical CRO footprint.
- **Q1 2025: ICON plc Launches Dedicated Oncology In Vivo CRO Unit** ICON plc launched a new business unit focused exclusively on in vivo oncology CRO services, aiming to meet rising demand for preclinical cancer research support.
- **Q2 2025: Envigo Appoints New Chief Scientific Officer to Lead Oncology In Vivo CRO Expansion** Envigo appointed a new Chief Scientific Officer to oversee the expansion of its in vivo oncology CRO services, reflecting the company’s commitment to advancing preclinical cancer research.
- **Q2 2025: Pharmaron Secures Major Contract for In Vivo Oncology Studies with Global Pharma Leader** Pharmaron secured a significant contract to provide in vivo oncology CRO services for a leading global pharmaceutical company, supporting preclinical cancer drug development.
- **Q3 2025: CRO Leader BioDuro-Sundia Raises $100 Million to Expand In Vivo Oncology Research Capabilities** BioDuro-Sundia raised $100 million in new funding to expand its in vivo oncology research capabilities, including facility upgrades and new technology platforms.
- **Q3 2025: Medpace Launches New Suite of In Vivo Oncology CRO Services for Biotech Startups** Medpace launched a new suite of in vivo oncology CRO services tailored for biotech startups, aiming to accelerate early-stage cancer drug development.

## **Oncology-based in vivo CRO Market Segmentation**

### **Oncology-based in vivo CRO Indication Outlook**

- Blood cancer
- Solid tumors
- Others

### **Oncology-based in vivo CRO Model Outlook**

- Syngeneic model
- Xenograft

### **Oncology-based in vivo CRO Regional Outlook**

**North America**

- US
- Canada

**Europe**

- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe

**Asia-Pacific**

- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific

**Rest of the World**

- Middle East
- Africa
- Latin America

## Market Drivers

### Growing Incidence of Cancer

The increasing prevalence of cancer worldwide is a primary driver for the Oncology-based in vivo CRO Market. According to the World Health Organization, cancer cases are projected to rise significantly, with an estimated 29.5 million new cases expected by 2040. This alarming trend necessitates the development of innovative therapies and treatments, thereby propelling demand for in vivo CRO services. As pharmaceutical companies and biotech firms seek to expedite their drug development processes, the reliance on specialized CROs for preclinical and clinical studies becomes paramount. The Oncology-based in vivo CRO Market is thus positioned to experience substantial growth as stakeholders aim to address the urgent need for effective cancer therapies.

### Regulatory Support for Cancer Research

Regulatory bodies are increasingly supportive of cancer research initiatives, which serves as a catalyst for the Oncology-based in vivo CRO Market. Initiatives such as the FDA's Breakthrough Therapy Designation and accelerated approval pathways encourage the development of novel cancer therapies. This regulatory environment fosters collaboration between CROs and pharmaceutical companies, facilitating faster and more efficient clinical trials. As a result, the Oncology-based in vivo CRO Market is expected to expand, driven by the need for compliance with evolving regulatory standards and the pursuit of expedited drug approvals.

### Rising Investment in Oncology Research

Investment in oncology research is witnessing a notable surge, significantly impacting the Oncology-based in vivo CRO Market. Venture capital funding and public-private partnerships are increasingly directed towards cancer research initiatives, with billions of dollars allocated annually. This influx of capital enables CROs to enhance their capabilities and expand their service offerings, thereby attracting more clients. The Oncology-based in vivo CRO Market is poised for growth as stakeholders capitalize on these investments to develop innovative cancer therapies and improve patient outcomes.

### Advancements in Drug Development Technologies

Technological innovations in drug development are reshaping the landscape of the Oncology-based in vivo CRO Market. The integration of advanced methodologies such as CRISPR gene editing, high-throughput screening, and sophisticated imaging techniques enhances the efficiency and accuracy of preclinical studies. These advancements allow for more precise targeting of cancer cells and improved understanding of tumor biology. As a result, pharmaceutical companies are increasingly outsourcing their research to specialized CROs that possess these cutting-edge technologies. The Oncology-based in vivo CRO Market is likely to benefit from this trend, as the demand for innovative solutions in drug development continues to rise.

### Increasing Demand for Outsourcing Preclinical Studies

The trend of outsourcing preclinical studies is gaining momentum, particularly in the Oncology-based in vivo CRO Market. Pharmaceutical and biotechnology companies are recognizing the advantages of partnering with specialized CROs to streamline their research processes. By outsourcing, these companies can access expertise, reduce operational costs, and accelerate their drug development timelines. This shift towards outsourcing is likely to continue, as more organizations seek to leverage the specialized knowledge and resources offered by CROs. Consequently, the Oncology-based in vivo CRO Market is expected to thrive as demand for outsourced services grows.

## Future Outlook

The Oncology-based in vivo CRO Market is projected to grow at an 8.3% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising R&D investments.

**New opportunities:**

- Integration of AI-driven data analytics for enhanced trial efficiency.
- Development of personalized medicine models to attract pharmaceutical partnerships.
- Expansion into emerging markets with tailored service offerings.

By 2035, the market is expected to solidify its position as a leader in oncology research services.

## Segment Insights

### By Indication: Blood Cancer (Largest) vs. Solid Tumors (Fastest-Growing)

In the oncology-based in vivo CRO market, the indication segment reveals significant variations in market share distribution. Blood cancer is currently the largest segment, commanding a notable share due to the rising prevalence of hematological malignancies and advancements in treatment methodologies. Solid tumors follow, exhibiting an increasing market presence as targeted therapies and immunotherapies gain traction. The growing focus on [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925) further enhances the relevance of clinical trials for solid tumors, paving the way for innovative therapeutic approaches.

Blood Cancer (Dominant) vs. Solid Tumors (Emerging)

Blood cancer, as the dominant indication in the oncology-based in vivo CRO market, is characterized by a high demand for specialized preclinical models, particularly in leukemia and lymphoma. Companies are increasingly investing in research to develop novel therapies, which elevates the role of CROs in facilitating efficient drug development processes. On the other hand, solid tumors are emerging as a fast-growing segment, driven by the rising incidence of various cancers such as breast, lung, and colorectal. The increasing complexity of solid tumor biology demands advanced in vivo models that CROs are uniquely positioned to provide, enhancing their service offerings and opening avenues for innovative treatment strategies.

### By Model: Syngeneic Model (Largest) vs. Xenograft (Fastest-Growing)

In the Oncology-based in vivo CRO Market, the syngeneic model currently commands a substantial portion of the market share, primarily due to its cost-effectiveness and efficient replication of the tumor microenvironment. This model is predominantly used for preclinical cancer research, providing insights that are critical to the development of effective therapies. On the other hand, the xenograft segment, which involves transplanting human tumors into immunocompromised mice, is gaining traction and expected to rapidly increase its presence due to its relevance in simulating human responses to treatments.

Model: Syngeneic (Dominant) vs. Xenograft (Emerging)

The syngeneic model is recognized for its robustness and reliability in cancer research, as it maintains the genetic consistency necessary to replicate reactions to treatment accurately. This model allows for a deeper understanding of tumor biology and has been traditionally favored for immuno-oncology studies. In contrast, the xenograft model is emerging strongly in the market, primarily because it offers a more relevant platform for testing human tumor behavior and therapeutic responses. Its ability to incorporate human immune cells and enhance the human relevance of preclinical studies is driving its rapid adoption among researchers, making it an essential component of contemporary oncology-based in vivo studies.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for oncology-based in vivo CRO services, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a strong regulatory framework that encourages innovation. The increasing prevalence of cancer and the demand for personalized medicine are key growth drivers, alongside supportive government initiatives aimed at accelerating drug development. The United States is the leading country in this sector, hosting major players like Charles River Laboratories and Covance. The competitive landscape is characterized by a mix of established firms and emerging biotech companies, all vying for a share of the growing market. Canada also plays a significant role, contributing to the region's overall growth with its robust clinical trial framework and collaboration with U.S. firms.

### Europe : Emerging Market with Growth Potential

Europe is the second-largest market for oncology-based in vivo CRO services, accounting for approximately 30% of the global market share. The region is witnessing a surge in demand driven by increasing cancer incidences and a growing focus on innovative therapies. Regulatory bodies like the European Medicines Agency (EMA) are actively streamlining approval processes, which enhances the attractiveness of the market for CROs and pharmaceutical companies alike. Leading countries in Europe include Germany, France, and the United Kingdom, which are home to several key players such as Eurofins Scientific and Syneos Health. The competitive landscape is marked by a mix of local and international firms, fostering collaboration and innovation. The presence of strong academic institutions further supports research and development efforts, making Europe a vital hub for oncology research.

### Asia-Pacific : Rapidly Growing Market Landscape

Asia-Pacific is emerging as a significant player in the oncology-based in vivo CRO market, holding about 20% of the global market share. The region's growth is fueled by increasing investments in healthcare infrastructure, a rising number of clinical trials, and a growing patient population. Countries like China and India are witnessing rapid advancements in biotechnology and pharmaceuticals, supported by favorable government policies aimed at enhancing research capabilities. China is the largest market in the region, with companies like Wuxi AppTec leading the charge. India is also gaining traction, with a burgeoning CRO sector that attracts global partnerships. The competitive landscape is evolving, with both local and international firms expanding their presence, driven by the need for cost-effective and efficient research solutions in oncology.

### Middle East and Africa : Emerging Opportunities in Healthcare

The Middle East and Africa region is gradually developing its oncology-based in vivo CRO market, currently holding about 5% of the global market share. The growth is primarily driven by increasing healthcare investments, rising cancer awareness, and the establishment of regulatory frameworks that support clinical research. Countries like South Africa and the UAE are leading the way, with initiatives aimed at improving healthcare access and research capabilities. South Africa is the most prominent market in the region, with a growing number of CROs and partnerships with international firms. The competitive landscape is still in its nascent stages, but there is a clear trend towards collaboration between local and global players. As the region continues to invest in healthcare infrastructure, the oncology CRO market is expected to gain further momentum.

## Competitive Benchmarking

The Oncology-based in vivo Contract Research Organization (CRO) Market is characterized by a dynamic competitive landscape, driven by the increasing demand for innovative cancer therapies and the need for efficient drug development processes. Key players such as Charles River Laboratories (US), Covance (US), and Wuxi AppTec (CN) are strategically positioned to leverage their extensive expertise in preclinical and clinical research. These companies focus on enhancing their service offerings through technological advancements, partnerships, and geographic expansion, thereby shaping a competitive environment that emphasizes quality and speed in drug development.
In terms of business tactics, companies are increasingly localizing their operations to better serve regional markets and optimize supply chains. The market appears moderately fragmented, with a mix of large multinational firms and smaller specialized entities. This structure allows for a diverse range of services and expertise, which collectively influences the competitive dynamics, as companies strive to differentiate themselves through specialized capabilities and innovative solutions.
In August 2025, Charles River Laboratories (US) announced the acquisition of a leading oncology-focused CRO, which is expected to enhance its capabilities in preclinical oncology research. This strategic move not only expands Charles River's service portfolio but also positions the company to better meet the growing demand for oncology drug development services. The acquisition reflects a broader trend in the industry where consolidation is seen as a means to achieve operational efficiencies and broaden therapeutic expertise.
Similarly, in July 2025, Covance (US) launched a new suite of digital tools aimed at streamlining clinical trial processes for oncology studies. This initiative underscores Covance's commitment to integrating technology into its operations, thereby improving data management and patient engagement. The introduction of these tools is likely to enhance Covance's competitive edge by providing clients with faster and more reliable trial outcomes, which is increasingly critical in the fast-paced oncology sector.
In September 2025, Wuxi AppTec (CN) expanded its global footprint by establishing a new research facility in Europe, specifically targeting oncology research. This expansion is indicative of Wuxi's strategy to tap into the European market's growing demand for innovative cancer therapies. By enhancing its geographical presence, Wuxi AppTec aims to foster closer collaborations with local biotech firms and academic institutions, thereby accelerating the development of novel oncology treatments.
As of October 2025, the Oncology-based in vivo CRO Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in research processes. Strategic alliances among key players are becoming increasingly prevalent, as companies seek to combine their strengths to enhance service offerings and drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, operational reliability, and the ability to deliver comprehensive, patient-centric solutions in oncology research.

## Recent News & Developments

- **Q2 2024: Charles River Laboratories Announces Opening of New Oncology Center of Excellence in Cambridge** Charles River Laboratories opened a new Oncology Center of Excellence in Cambridge, Massachusetts, aimed at expanding its in vivo oncology CRO capabilities and supporting preclinical cancer drug development.
- **Q2 2024: Crown Bioscience Expands In Vivo Oncology Services with New Facility in San Diego** Crown Bioscience announced the opening of a new facility in San Diego dedicated to in vivo oncology research, enhancing its capacity for preclinical CRO services in cancer drug discovery.
- **Q3 2024: WuXi AppTec Launches Advanced In Vivo Oncology Platform to Accelerate Immuno-Oncology Drug Development** WuXi AppTec launched a new in vivo oncology platform designed to support immuno-oncology drug development, offering expanded preclinical CRO services for pharmaceutical and biotech clients.
- **Q3 2024: Labcorp Acquires Preclinical Oncology CRO, Expands In Vivo Cancer Research Services** Labcorp completed the acquisition of a specialized preclinical oncology CRO, strengthening its in vivo cancer research service offerings for global biopharma clients.
- **Q4 2024: Evotec and Bristol Myers Squibb Announce Strategic Partnership for In Vivo Oncology Drug Discovery** Evotec entered a strategic partnership with Bristol Myers Squibb to collaborate on in vivo oncology drug discovery, leveraging Evotec’s CRO expertise to accelerate cancer therapy development.
- **Q4 2024: Syngene International Opens New Preclinical Oncology Research Facility in Bangalore** Syngene International inaugurated a new preclinical oncology research facility in Bangalore, expanding its in vivo CRO capabilities for global pharmaceutical clients.
- **Q1 2025: Eurofins Scientific Acquires Oncology-Focused CRO to Bolster In Vivo Cancer Research Portfolio** Eurofins Scientific acquired a US-based oncology-focused CRO, enhancing its in vivo cancer research services and expanding its global preclinical CRO footprint.
- **Q1 2025: ICON plc Launches Dedicated Oncology In Vivo CRO Unit** ICON plc launched a new business unit focused exclusively on in vivo oncology CRO services, aiming to meet rising demand for preclinical cancer research support.
- **Q2 2025: Envigo Appoints New Chief Scientific Officer to Lead Oncology In Vivo CRO Expansion** Envigo appointed a new Chief Scientific Officer to oversee the expansion of its in vivo oncology CRO services, reflecting the company’s commitment to advancing preclinical cancer research.
- **Q2 2025: Pharmaron Secures Major Contract for In Vivo Oncology Studies with Global Pharma Leader** Pharmaron secured a significant contract to provide in vivo oncology CRO services for a leading global pharmaceutical company, supporting preclinical cancer drug development.
- **Q3 2025: CRO Leader BioDuro-Sundia Raises $100 Million to Expand In Vivo Oncology Research Capabilities** BioDuro-Sundia raised $100 million in new funding to expand its in vivo oncology research capabilities, including facility upgrades and new technology platforms.
- **Q3 2025: Medpace Launches New Suite of In Vivo Oncology CRO Services for Biotech Startups** Medpace launched a new suite of in vivo oncology CRO services tailored for biotech startups, aiming to accelerate early-stage cancer drug development.

## Report Scope

| MARKET SIZE 2024 | 1.397(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.513(USD Billion) |
| MARKET SIZE 2035 | 3.36(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Charles River Laboratories (US), Covance (US), PRA Health Sciences (US), Medpace (US), Eurofins Scientific (LU), Syneos Health (US), Wuxi AppTec (CN), OncoOne (CH), Kymab (GB) |
| Segments Covered | Indication, Model, Region |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative Oncology-based in vivo CRO Market solutions. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the Oncology-based in vivo Contract Research Organization market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Oncology-based in vivo CRO Market?**
A: As of 2024, the market valuation stood at 1.397 USD Billion.

**Q: What is the projected market size for the Oncology-based in vivo CRO Market by 2035?**
A: The market is projected to reach 3.36 USD Billion by 2035.

**Q: What is the expected CAGR for the Oncology-based in vivo CRO Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 8.3%.

**Q: Which segments are included in the Oncology-based in vivo CRO Market?**
A: The market segments include Blood cancer, Solid tumors, and Others under Indication, and Syngeneic model and Xenograft under Model.

**Q: What were the valuations for Blood cancer and Solid tumors in 2024?**
A: In 2024, Blood cancer was valued at 0.419 USD Billion, while Solid tumors were valued at 0.698 USD Billion.

**Q: What is the projected valuation for the Solid tumors segment by 2035?**
A: The Solid tumors segment is projected to reach 1.63 USD Billion by 2035.

**Q: Who are the key players in the Oncology-based in vivo CRO Market?**
A: Key players include Charles River Laboratories, Covance, PRA Health Sciences, Medpace, Eurofins Scientific, Syneos Health, Wuxi AppTec, OncoOne, and Kymab.

**Q: What is the projected growth for the Xenograft model segment by 2035?**
A: The Xenograft model segment is projected to grow to 2.4 USD Billion by 2035.

**Q: How does the market performance of the Syngeneic model compare to the Xenograft model?**
A: In 2024, the Syngeneic model was valued at 0.558 USD Billion, while the Xenograft model was valued at 0.839 USD Billion.

**Q: What does the future hold for the Oncology-based in vivo CRO Market?**
A: The market appears poised for substantial growth, potentially reaching 3.36 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/oncology-based-in-vivo-cro-market-21721*